Frontlight ResearchEarly access
Not yet taking people in United StatesPhase 2
PET Scan Tracer to Track Lung Scarring in Systemic Sclerosis
Tests a PET scan tracer in adults with systemic sclerosis lung disease.
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- FAPI PET in Systemic Sclerosis Interstitial Lung Disease
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- Nov 2026
- Expected to end
- Jun 2030
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- FAPI tracer
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Ability to provide written informed consent
- Male or female > 18 years of age at the screening visit
- Meets the 2013 American College of Rheumatology (ACR)/EULAR Classification Criteria for SSc
- ILD confirmed by thoracic high resolution computed tomography (HRCT) at the baseline visit
- Initiated or will initiate a new ILD therapy within the last 3 months +/- 1 week prior to the screening visit
- If enrolled in the FAPI/PET group, women of child-bearing potential must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnant test will be required
Who cannot take part
- Subjects must not have participated in another clinical trial with an investigational product within 90 days prior to enrollment and agree to abstain from such trials during the study
- Prior allergic reaction to radiotracer 68Ga-FAPI-46
- Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study
- Active infectious lung disease
- Current malignancy other than squamous or basal cell carcinoma
- Current lung disease other than ILD (e.g., emphysema)
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
Where in United States
- UCLA Division of RheumatologyLos Angeles, United StatesContact: Nahal E Ghanoongooi, CRC, MPHNot yet recruiting
About the trial
What the trial wants to find out
This is a phase II open-label efficacy and safety study to evaluate standard of care treatment response measured by PET imaging radiotracer 68Ga-FAPI-46 in 120 subjects with SSc-ILD.
The 2 groups in the trial
- Receive PET ScanTreatment being tested
Treatment: FAPI tracer
- Blood Draw OnlyNo study treatment, for comparison
Control arm, no intervention
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase II Open-label Efficacy And Safety Study of Fibroblast Activation Protein α (FAP)-Directed Radiotracer 68Ga-FAPI-46 As a Positron Emission Tomography (PET) Functional Response Biomarker For Systemic Sclerosis-Associated Interstitial Lung Disease (SSC-ILD)
- Plain-language title
- PET Scan Tracer to Track Lung Scarring in Systemic SclerosisGenerated from the registry record. The registry title is the official one.
- Record updated
- 12 November 2026